Vyluma Inc. Launches With Robust Opthalmic Portfolio, Leading With A Pharmaceutical Treatment In Phase III For Myopia

The robust pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eyedrop to slow the progression of myopia in children.